Merck & Co Inc (MRK.DE) Q1 2026 Earnings Call Transcript
Neutral Drug Manufacturers - Specialty & Generic 299.26B USA
Next Earnings
2026-10-29
There is no Profile data available for MRK.SG.
Merck met its 2025 guidance amid FX headwinds and outlined a cautious 2026 plan anchored in three growth platforms and portfolio changes.
⭐ Key Highlights
2025 performance aligned with guidance
Merck delivered on its 2025 guidance with net sales around €21.1b and EBITDA pre €6.1b, despite strong FX headwinds.
Strategic diversification and growth platforms confirmed
Growth remains anchored in three platforms: Process Solutions in Life Science, rare diseases in Healthcare, and semiconductor solutions in Electronics, with AI and advanced therapies highlighted as key drivers.
Mavenclad and Pergoveris trajectory discussed
Mavenclad faces generic competition in the U.S., contributing to transition plans; Pergoveris timing remains uncertain but potential U.S. approval is expected later, with SpringWorks now a growth pillar.
2026 guidance and assumptions laid out
Guidance for 2026: group net sales €20–€21.1b and EBITDA pre €5.5–€6.0b, with organic -1% to -2%, reflecting portfolio changes (SpringWorks, Surface Solutions) and FX volatility.
Management succession and long-term strategy
Belen Garijo steps down as CEO in 2026 with Kai Beckmann taking over, while the company emphasizes a region-for-region approach and continued investment in Darmstadt.
✔Positive Signals
- Guidance for 2025 met despite currency headwinds
- Strategic portfolio moves: SpringWorks acquisition and Unity-SC integration contributing to growth
- Three growth platforms identified: Process Solutions, rare diseases, and semiconductor solutions
- High investment in innovation and site expansion supporting future growth
- U.S. access agreement for IVF therapies improving market positioning
✖Negative Signals
- Significant foreign exchange headwinds impacting sales and EBITDA
- Mavenclad loss of exclusivity in the U.S. creates near-term revenue risk
- DS&S headwinds in Electronics due to large customer project delays
- Uncertainty around Pergoveris timing and U.S. market dynamics
- Geopolitical tensions and regulatory uncertainty create near-term execution risk
📊Financial Results
- Net sales for 2025 were around €21.1 billion, roughly flat versus prior guidance, with FX headwinds of about 4% reducing reported sales
- EBITDA pre for 2025 was €6.1 billion, margin 28.9% of net sales, up 5.6% organically
- Life Science organic sales up 4%; Process Solutions drove the growth; EBITDA pre margin essentially stable at ~28.8%
- Healthcare organic sales +3.7% with FX headwind of ~4.1%; Mavenclad and Pergoveris contributed to earnings growth
- Electronics organic sales down ~0.6% for the year; semiconductor materials offset DS&S weakness; EBITDA pre lower by ~9% driven by second-quarter onetime adjustments
🔮Future Guidance
- 2026 guidance: group net sales €20.0–€21.1 billion; group EBITDA pre €5.5–€6.0 billion; organic revenue -1% to -2%
- Assumptions include SpringWorks and Surface Solutions portfolio effects in H2 2026, no U.S. Mavenclad sales from March 2026 amid generic competition, and uncertain potential Pergoveris U.S. launch
- FX headwinds expected to persist into 2026 with more volatility, especially from the U.S. dollar and various Asian currencies
💡Interesting Insights
- Merck emphasizes a region-for-region approach to mitigate geopolitical risk, reinforcing Asia-Pacific as a major revenue source and guiding capital allocation locally
Detailed Analysis
AI-generated summary of Merck & Co Inc earnings call transcript.
In 2025, Merck aligned with its guidance despite geopolitical and currency challenges, showcasing resilience through a diversified regional model and leadership transitions. The Life Science segment benefited from strong Process Solutions growth, Healthcare posted solid organic gains with Mavenclad and Fertility contributing, and Electronics recovered late in the year on AI-driven semiconductor demand, aided by the Unity-SC acquisition and a new Taiwan megasite. The company announced SpringWorks as a new growth pillar in rare diseases and outlined an agreement with the U.S. administration to improve access to IVF therapies, while a strategic review of the CDMO business continues. For 2026, management guided currency- and portfolio-driven expectations: net sales of €20–€21.1b and EBITDA pre of €5.5–€6.0b, with organic growth of -1% to -2%, reflecting continued FX headwinds and the timing of Mavenclad and Pergoveris developments. Belen Garijo is stepping down as CEO in 2026, with Kai Beckmann taking over, and the firm reaffirmed its commitment to Darmstadt and a region-for-region growth strategy amid ongoing geopolitical uncertainty.
Get Real-Time Earnings Call Alerts for Merck & Co Inc
Create a free MarketAlerts account to add MRK.DE to your watchlist and receive instant AI-powered alerts when new earnings call transcripts, insider trades, and technical signals are detected.
Other MarketAlerts Features
